Incidence and impact of food aversions among patients with cancer receiving outpatient chemotherapy: a one-year prospective survey.

Abstract

Purpose: To determine the current incidence and impact of chemotherapy-associated food aversions in a variety of cancer types.

Methods: Cancer patients aged 18 years and older who received chemotherapy infusions at the outpatient chemotherapy unit of a university hospital between May 2022 and April 2023 were included in the study (n = 243). To monitor the occurrence of food aversions, participants were asked to complete a food preference questionnaire each time they visited the outpatient chemotherapy unit.

Results: During the one-year survey period, one in four cancer patients receiving outpatient chemotherapy developed food aversions, and one in four of them complained of interference with daily life due to eating problems at the same time or later. The median time to the onset of food aversion was 46 (interquartile range 36-77) days after the start of chemotherapy. The incidence of food aversions was significantly higher in patients who were women, had a digestive, gynecologic, or breast cancer, and received more cytotoxic agents in chemotherapy. Patients who developed food aversions tended to lose more body weight than those who did not.

Conclusion: Food aversions were still common among cancer patients undergoing chemotherapy. Even an aversion to a single food may have affected the patient's nutritional status. Healthcare professionals should closely monitor the occurrence of food aversions, especially in the early days of chemotherapy induction, to detect an increasing risk of malnutrition.

Trial registration: Not applicable.